GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (NSE:GUFICBIO) » Definitions » Cyclically Adjusted PS Ratio

Gufic Biosciences (NSE:GUFICBIO) Cyclically Adjusted PS Ratio : 5.64 (As of Jun. 05, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Gufic Biosciences Cyclically Adjusted PS Ratio?

As of today (2025-06-05), Gufic Biosciences's current share price is ₹369.50. Gufic Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹65.55. Gufic Biosciences's Cyclically Adjusted PS Ratio for today is 5.64.

The historical rank and industry rank for Gufic Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:GUFICBIO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.5   Med: 5.01   Max: 7.78
Current: 5.65

During the past years, Gufic Biosciences's highest Cyclically Adjusted PS Ratio was 7.78. The lowest was 2.50. And the median was 5.01.

NSE:GUFICBIO's Cyclically Adjusted PS Ratio is ranked worse than
83.33% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.155 vs NSE:GUFICBIO: 5.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gufic Biosciences's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹20.455. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹65.55 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gufic Biosciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Gufic Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gufic Biosciences Cyclically Adjusted PS Ratio Chart

Gufic Biosciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 5.74 3.67 4.82 5.13

Gufic Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 5.68 6.12 7.07 5.13

Competitive Comparison of Gufic Biosciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Cyclically Adjusted PS Ratio falls into.


;
;

Gufic Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Gufic Biosciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=369.50/65.55
=5.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Gufic Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=20.455/157.5517*157.5517
=20.455

Current CPI (Mar. 2025) = 157.5517.

Gufic Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 4.698 99.841 7.414
201509 6.526 101.753 10.105
201512 7.188 102.901 11.006
201603 6.550 102.518 10.066
201606 7.097 105.961 10.552
201609 8.229 105.961 12.236
201612 8.294 105.196 12.422
201703 7.763 105.196 11.627
201706 7.829 107.109 11.516
201709 9.614 109.021 13.894
201712 11.535 109.404 16.611
201803 10.031 109.786 14.395
201806 11.721 111.317 16.589
201809 11.801 115.142 16.148
201812 11.329 115.142 15.502
201903 10.813 118.202 14.413
201906 11.937 120.880 15.558
201909 10.994 123.175 14.062
201912 12.532 126.235 15.641
202003 13.192 124.705 16.667
202006 6.363 127.000 7.894
202009 13.264 130.118 16.061
202012 17.232 130.889 20.742
202103 13.672 131.771 16.347
202106 25.874 134.084 30.402
202109 20.049 135.847 23.252
202112 17.753 138.161 20.245
202203 9.893 138.822 11.228
202206 17.037 142.347 18.857
202209 18.079 144.661 19.690
202212 18.327 145.763 19.809
202303 16.760 146.865 17.980
202306 20.142 150.280 21.117
202309 22.127 151.492 23.012
202312 20.217 152.924 20.829
202403 19.406 153.035 19.979
202406 20.227 155.789 20.456
202409 20.354 157.882 20.311
202412 20.774 158.323 20.673
202503 20.455 157.552 20.455

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gufic Biosciences  (NSE:GUFICBIO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Gufic Biosciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Gufic Biosciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gufic Biosciences Business Description

Traded in Other Exchanges
Address
SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.

Gufic Biosciences Headlines

No Headlines